

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

**Committee on Global Coordination, Partnerships, and Financing
Recommendations for Advancing Pandemic and Seasonal Influenza
Vaccine Preparedness and Response**

Third Committee Meeting Agenda
Technology & Manufacturing Partnerships Group

May 6, 2021 (8:00-10:00am EDT): *Three simultaneous working group sessions*
May 7, 2021 (9:00am-11:00am EDT): *Three simultaneous working group sessions*
May 14 (8:00am-11:00am EDT): *Single session*

Meeting Objectives

- Hold open sessions to obtain background from speakers on the current barriers for effective global health governance for pandemic influenza vaccination, with a focus on pathogen sharing regulations, technology transfer partnerships, and global access and financing
- Hold working group deliberations to form initial recommendations
- Hold whole-committee meeting to discuss initial recommendations and next steps

Thursday, 6 May

CLOSED SESSION: COMMITTEE MEMBERS ONLY

8:00 a.m. – 8:25 a.m.

Discussion Objectives:

- Hear from Richard Hatchett about CEPI's current role in influenza R&D/manufacturing, and discuss CEPI's role (potentially in the context of human capital in vaccine development)
- Discuss questions for next speaker (Joe Bresee)

OPEN SESSION 1

8:25 a.m. **Welcome & Introductions**

Bruce Gellin
Director, Global Immunization
Sabin Vaccine Institute

8:30 a.m. **Speaker 1: Public-Private Partnerships for Influenza Vaccine Development & Manufacturing & the Center for Infectious Disease Research And Policy (CIDRAP)’s Influenza Vaccine R&D Road-Map**

*Joseph Bresee
Influenza Division Associate Director of Global Health Affairs,
U.S. Centers for Disease Control and Prevention
Director, Partnership for Influenza Vaccine Introduction
Director, Global Funders Consortium for Universal Influenza Vaccine
Development*

8:55 a.m. **Closing Remarks**

CLOSED SESSION: COMMITTEE MEMBERS ONLY

9:00 a.m. – 10:00 a.m.

Discussion Objectives:

- Review gaps identified in previous meetings (Google Doc)
- Delineate the areas in which this working group will make recommendations
- Begin to form findings/conclusions/recommendations (reminder: we’ll aim for 3-4 recommendations per group, each of which can have layered/sub-recommendations as needed)
- Discuss any specific questions that should be asked of tomorrow’s speaker (Jim Robinson)

Friday, 7 May

OPEN SESSION 2

9:00 a.m. **Welcome & Introductions**

*Bruce Gellin
Director, Global Immunization
Sabin Vaccine Institute*

9:05 a.m. **Speaker 1: The Coalition for Epidemic Preparedness & Innovations (CEPI)’s Role as a Broker and Facilitator of Manufacturing Partnerships**

*James Robinson
CEPI Scientific Advisory Committee Vice Chair
James Robinson Biologics Consulting*

9:30 a.m. **Closing Remarks**

CLOSED SESSION: COMMITTEE MEMBERS ONLY

9:30 a.m. – 11:00a.m.

Discussion Objectives:

- Discuss findings/conclusions/recommendations made yesterday, in light of information gathered today
- Identify any data, case studies, or summaries that are required from the NASEM team for this working group to form recommendations
- Determine if members would like to take on specific roles/topics within this working group

Friday, 14 May

CLOSED SESSION: COMMITTEE MEMBERS ONLY

8:00a.m. – 11:00a.m.

Agenda TBD, depending on working group progress. It will most likely include:

1. Short presentation from NASEM Executive Office on how to write findings/conclusions/recommendations, with Q&A (20 min)
2. Time for working group meeting (45 min – 1 hr?)
3. Whole committee discussions (1.5 hr):
 - a. Working group current areas of concentration/interim recommendations (short presentation from each group leader)
 - b. Framing of influenza and respiratory diseases within the report (discussion of Ok's circulated treatise)
 - c. Ideas for report title
 - d. Perspective on Chapter 1 (Intro) draft
 - e. Airfinity's influenza manufacturing and technology partnerships data
 - f. Speakers and questions to ask during the NAM's International Committee's meetings next week (One Health and surveillance, COVAX and incentives, etc.)